An expert discusses how recent updates to AUA, EAU and NCCN guidelines have cautiously shifted toward more bladder-sparing approaches for BCG-unresponsive patients, incorporating new FDA-approved ...

Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

AUA 2025 upstaging and risk migration with blue light cystoscopy for non muscle invasive bladder cancer, white light cystoscopy, Cysview Registry, blue light cystoscopy.

Press Release - Oslo, Norway, April 29, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

"At AUA and EAU 2025 congresses we have seen important expert alignment these past weeks on the importance of early and accurate precision diagnosis in bladder cancer, and the role of blue light ...

"At AUA and EAU 2025 congresses we have seen important expert alignment these past weeks on the importance of early and accurate precision diagnosis in bladder cancer, and the role of blue light ...

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC ®).